JP2010531854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531854A5 JP2010531854A5 JP2010513980A JP2010513980A JP2010531854A5 JP 2010531854 A5 JP2010531854 A5 JP 2010531854A5 JP 2010513980 A JP2010513980 A JP 2010513980A JP 2010513980 A JP2010513980 A JP 2010513980A JP 2010531854 A5 JP2010531854 A5 JP 2010531854A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- compound
- amino
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 148
- 125000005843 halogen group Chemical group 0.000 claims description 127
- 239000008194 pharmaceutical composition Substances 0.000 claims description 62
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 46
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 43
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 43
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 210000004556 brain Anatomy 0.000 claims description 27
- 125000004122 cyclic group Chemical group 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 230000001149 cognitive effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 206010027175 memory impairment Diseases 0.000 claims description 13
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 12
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 12
- 230000007087 memory ability Effects 0.000 claims description 12
- 208000010877 cognitive disease Diseases 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 9
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 9
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 8
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 230000003111 delayed effect Effects 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 6
- 229960003530 donepezil Drugs 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229960004136 rivastigmine Drugs 0.000 claims description 6
- 229960001685 tacrine Drugs 0.000 claims description 6
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 6
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 5
- 230000007351 Aβ plaque formation Effects 0.000 claims description 5
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims description 5
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 5
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 201000010374 Down Syndrome Diseases 0.000 claims description 5
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 5
- 201000010901 lateral sclerosis Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 208000005264 motor neuron disease Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 claims description 4
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 206010061323 Optic neuropathy Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 230000006933 amyloid-beta aggregation Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229960003980 galantamine Drugs 0.000 claims description 4
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- -1 monosubstituted amino Chemical group 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000020911 optic nerve disease Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 102000013498 tau Proteins Human genes 0.000 claims description 4
- 108010026424 tau Proteins Proteins 0.000 claims description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 2
- 208000018282 ACys amyloidosis Diseases 0.000 claims description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims description 2
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 2
- 206010048327 Supranuclear palsy Diseases 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004373 acetylcholine Drugs 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 230000001668 ameliorated effect Effects 0.000 claims description 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229960004372 aripiprazole Drugs 0.000 claims description 2
- 239000005667 attractant Substances 0.000 claims description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 2
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 2
- 239000002439 beta secretase inhibitor Substances 0.000 claims description 2
- 229940088623 biologically active substance Drugs 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 230000031902 chemoattractant activity Effects 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004170 clozapine Drugs 0.000 claims description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 claims description 2
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims description 2
- 229960004135 idebenone Drugs 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 210000004558 lewy body Anatomy 0.000 claims description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229960005017 olanzapine Drugs 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 claims description 2
- 229940043131 pyroglutamate Drugs 0.000 claims description 2
- 229960001534 risperidone Drugs 0.000 claims description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 229960000607 ziprasidone Drugs 0.000 claims description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07111491 | 2007-07-02 | ||
| PCT/EP2008/058527 WO2009004038A2 (en) | 2007-07-02 | 2008-07-02 | Therapeutic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531854A JP2010531854A (ja) | 2010-09-30 |
| JP2010531854A5 true JP2010531854A5 (enExample) | 2010-11-11 |
Family
ID=40020257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513980A Withdrawn JP2010531854A (ja) | 2007-07-02 | 2008-07-02 | 抗アミロイド剤としてのピレンゼピンおよびその誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100247688A1 (enExample) |
| EP (1) | EP2173355A2 (enExample) |
| JP (1) | JP2010531854A (enExample) |
| KR (1) | KR20100038424A (enExample) |
| CN (1) | CN101778634A (enExample) |
| AU (1) | AU2008270247A1 (enExample) |
| BR (1) | BRPI0812849A2 (enExample) |
| CA (1) | CA2691844A1 (enExample) |
| IL (1) | IL202768A0 (enExample) |
| MX (1) | MX2009014126A (enExample) |
| NZ (1) | NZ582314A (enExample) |
| RU (1) | RU2010103105A (enExample) |
| WO (1) | WO2009004038A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2379080A1 (en) | 2009-01-13 | 2011-10-26 | ProteoSys AG | Pirenzepine as otoprotective agent |
| ES2693152T3 (es) | 2011-05-10 | 2018-12-07 | Kyowa Hakko Kirin Co., Ltd. | Compuesto de pirimido-diazepinona |
| WO2013068592A1 (en) * | 2011-11-10 | 2013-05-16 | Fondation Jerome Lejeune | Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide |
| CA3192987A1 (en) * | 2020-09-22 | 2022-03-31 | Kathleen E. Clarence-Smith | Pharmaceutical combination for the treatment of human hypocholinergic disorders |
| CN116635034A (zh) * | 2020-09-22 | 2023-08-22 | K·E·克拉伦斯-史密斯 | 用于治疗人低胆碱能障碍的药物组合 |
| JP2025502278A (ja) * | 2022-01-16 | 2025-01-24 | ウィンサンター・インコーポレイテッド | 性的感覚障害を改善するための組成物および方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1795183B1 (de) * | 1968-08-20 | 1972-07-20 | Thomae Gmbh Dr K | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel |
| DE3818299A1 (de) * | 1988-05-30 | 1989-12-07 | Thomae Gmbh Dr K | Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE4112014A1 (de) * | 1991-04-12 | 1992-10-15 | Thomae Gmbh Dr K | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel zur behandlung von erkrankungen des zentralnervensystems und zur foerderung der cerebralen durchblutung |
| CA2573673A1 (en) * | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
| CA2614385A1 (en) * | 2005-07-12 | 2007-01-18 | Abbott Gmbh & Co. Kg | Pyridazine compounds as glycogen synthase kinase 3 inhibitors |
-
2008
- 2008-07-02 CA CA002691844A patent/CA2691844A1/en not_active Abandoned
- 2008-07-02 MX MX2009014126A patent/MX2009014126A/es not_active Application Discontinuation
- 2008-07-02 US US12/667,445 patent/US20100247688A1/en not_active Abandoned
- 2008-07-02 NZ NZ582314A patent/NZ582314A/en not_active IP Right Cessation
- 2008-07-02 KR KR1020107002421A patent/KR20100038424A/ko not_active Withdrawn
- 2008-07-02 BR BRPI0812849-9A2A patent/BRPI0812849A2/pt not_active IP Right Cessation
- 2008-07-02 WO PCT/EP2008/058527 patent/WO2009004038A2/en not_active Ceased
- 2008-07-02 EP EP08774661A patent/EP2173355A2/en not_active Withdrawn
- 2008-07-02 JP JP2010513980A patent/JP2010531854A/ja not_active Withdrawn
- 2008-07-02 AU AU2008270247A patent/AU2008270247A1/en not_active Abandoned
- 2008-07-02 RU RU2010103105/15A patent/RU2010103105A/ru not_active Application Discontinuation
- 2008-07-02 CN CN200880103247A patent/CN101778634A/zh active Pending
-
2009
- 2009-12-16 IL IL202768A patent/IL202768A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11110097B2 (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| CN109475539B (zh) | 帕金森氏病的治疗 | |
| JP2010531854A5 (enExample) | ||
| IL272092B1 (en) | 5-((((1r,2s)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine for use in treating behavior alterations | |
| RU2010103105A (ru) | Пирензепин и его производные в качестве анти-амилоидных агентов | |
| JP2021167361A (ja) | 神経変性障害を処置するための方法 | |
| KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
| JP5469707B2 (ja) | 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物 | |
| EP3833354B1 (en) | Tissue transglutaminase modulators for medicinal use | |
| JP7535797B2 (ja) | 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法 | |
| JP6907174B2 (ja) | アミロイド線維形成の抑制又は阻害剤 | |
| WO2017035528A1 (en) | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau | |
| JP3494651B2 (ja) | 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用 | |
| HK40016881A (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| JP2024510249A (ja) | 神経疾患を治療するための組成物およびその方法 | |
| HK1213494B (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| JP2006505549A (ja) | 肥満の治療処置のための、脂質および炭水化物の代謝を刺激するヘテロ環式化合物と抗酸化剤の会合 | |
| HK1212603B (zh) | 治療阿爾茨海默病及相關疾病的組合療法 |